|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease显示文摘AIM: To evaluate the role of genetic factors in the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC), we investigated the single nucleotide poly- morphisms (SNPs) of NOD2/CARD15 (R702W, G908R and L1007fi nsC), and Toll-like receptor 4 (TLR4) genes (D299G and T399I) in a selected inflammatory bowel disease (IBD) population coming from Southern Italy. METHODS: Allele and genotype frequencies of NOD2/ CARD15 (R702W, G908R and L1007finsC) and TLR4 (D299G and T399I) SNPs were examined in 133 CD pa-tients, in 45 UC patients, and in 103 healthy controls. A genotype-phenotype correlation was performed. RESULTS: NOD2/CARD15 R702W mutation was sig-nificantly more frequent in CD (9.8%) than in controls (2.4%, P = 0.001) and in UC (2.3%, P = 0.03). No sig-nificant difference was found between UC patients and control group (P > 0.05). In CD and UC patients, no signifi cant association with G908R variant was found. L1007f insC SNP showed an association with CD (9.8%) compared with controls (2.9%, P = 0.002) and UC patients (2.3%, P = 0.01). Moreover, in CD patients, G908R and L1007finsC mutations were significantly associated with different phenotypes compared to CD wild-type patients. No association of IBD with the TLR4 SNPs was found in either cohort (allele frequencies: D299G-controls 3.9%, CD 3.7%, UC 3.4%, P > 0.05; T399I-controls 2.9%, CD 3.0%, UC 3.4%, P > 0.05). CONCLUSION: These findings confirm that, in our IBD patients selected from Southern Italy, the NOD2/ CARD15, but not TLR4 SNPs, are associated with in-creased risk of CD. | Luciana Rigoli Claudio Romano Rosario Alberto Caruso Maria A Lo Presti Chiara Di Bella Vincenzo Procopio Giuseppina Lo Giudice Maria Amorini Giuseppe Costantino Maria D Sergi Caterina Cuppari Giovanna Elisa Calabrò Romina Gallizzi Carmelo Damiano Salpietro Walter Fries | 2008 | World Journal of Gastroenterology2008，14，28： | 8 |
| 2 | Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?显示文摘 | Emilio Bajetta Laura Catena Giuseppe Procopio Sara Dosso Ettore Bichisao Leonardo Ferrari Antonia Martinetti Marco Platania Elena Verzoni Barbara Formisano Roberto Bajetta | 2007 | Cancer Chemotherapy and Pharmacology2007，，： | 2 |
| 3 | Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials显示文摘 | Matteo Santoni Alessandro Conti Francesco Massari Giorgio Arnaldi Roberto Iacovelli Mimma Rizzo Ugo Giorgi Laura Trementino Giuseppe Procopio Giampaolo Tortora Stefano Cascinu | 2015 | Int. J. Cancer2015，，： | 1 |
| 4 | Is there a role for targeted therapies in the collecting ducts of bellini carcino- ma? Efficacy data from a retrospective analysis of 7 cases显示文摘 | Giuseppe Procopio Elena Verzoni Roberto lacovelli | 2012 | Clin Exp Nephrol2012，16，3： | 1 |
| 5 | Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant显示文摘 | AMELIA ALTAVILLA ROBERTO1ACOVELLI GIUSEPPE PROCOPIO | 2012 | Cancer Biology -therapy2012，13，11： | 1 |
| 6 | Production of multiple cytokines by clones of human large granular lymphocytes显示文摘 | Paola Allavena Giuseppe Scala Julie Y. Djeu Antonio D. Procopio Joost J. Oppenheim Ronald B. Herberman John R. Ortaldo | 1985 | Cancer Immunology Immunotherapy1985，，2： | 1 |
| 7 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series显示文摘BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.New systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC cases.AIM To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODS The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTS Overall,48 patients were included.At the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,respectively.Grade 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were found.CONCLUSION Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology. | Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca | 2021 | World Journal of Clinical Oncology2021，12，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员